Search
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalMavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … by a reduced number of mature neutrophils and lymphocytes.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.
Phosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalBecause of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary supplement to people who believe they can benefit from an increased intake. … PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalNatalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin.
Soy isoflavones
go.drugbank.com/drugs/DB14101ApprovedMixtures: D-Cal SoyCal, ISOFLAVONA DE SOYA + VITAMINA D300 UI +CITRATO DE CALCIO.Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexInulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalA starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan.
Categories: Compounds used in a research, industrial, or household setting